Thelansis’s "Severe Hypertriglyceridemia (sHTG) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Severe Hypertriglyceridemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Severe hypertriglyceridemia is characterized by fasting triglycerides of at least 500 mg/dL and may result from genetic lipid disorders, obesity, diabetes, alcohol exposure, medications, or secondary factors. At very high levels, accumulation of triglyceride-rich lipoproteins, particularly chylomicrons, increases the risk of acute pancreatitis. Management focuses on correcting secondary causes, dietary fat restriction, limiting alcohol, improving glycemic control, and triglyceride-lowering therapy. Fibrates and prescription omega-3 fatty acids remain options. Therapeutic innovation increasingly targets apolipoprotein C-III (APOC3), a key regulator of triglyceride metabolism. Olezarsen, an APOC3-directed antisense oligonucleotide, is approved for familial chylomicronemia syndrome and, since 2026, for adults with severe hypertriglyceridemia to reduce triglycerides and pancreatitis risk. Plozasiran, an APOC3-directed siRNA, is approved for adults with familial chylomicronemia syndrome.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Severe Hypertriglyceridemia (sHTG) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report
Our team will get in touch with you shortly about the Severe Hypertriglyceridemia (sHTG) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report.